Cargando…

Vandetanib drives growth arrest and promotes sensitivity to imatinib in chronic myeloid leukemia by targeting ephrin type‐B receptor 4

The oncogenic role of ephrin type‐B receptor 4 (EPHB4) has been reported in many types of tumors, including chronic myeloid leukemia (CML). Here, we found that CML patients have a higher EPHB4 expression level than healthy subjects. EPHB4 knockdown inhibited growth of K562 cells (a human immortalize...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ma, Weina, Zhu, Man, Wang, Bo, Gong, Zhengyan, Du, Xia, Yang, Tianfeng, Shi, Xianpeng, Dai, Bingling, Zhan, Yingzhuan, Zhang, Dongdong, Ji, Yanhong, Wang, Yang, Li, Song, Zhang, Yanmin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9297786/ https://www.ncbi.nlm.nih.gov/pubmed/35689424 http://dx.doi.org/10.1002/1878-0261.13270

Ejemplares similares

HMQ‐T‐B10 induces human liver cell apoptosis by competitively targeting EphrinB2 and regulating its pathway
por: Dai, Bingling, et al.
Publicado: (2018)

Eupolyphaga sinensis Walker displays inhibition on hepatocellular carcinoma through regulating cell growth and metastasis signaling
por: Zhang, Yanmin, et al.
Publicado: (2014)

A novel tissue model for angiogenesis: evaluation of inhibitors or promoters in tissue level
por: Dai, Bingling, et al.
Publicado: (2014)

Selenium sulfide disrupts the PLAGL2/C‐MET/STAT3‐induced resistance against mitochondrial apoptosis in hepatocellular carcinoma
por: Yang, Tianfeng, et al.
Publicado: (2021)

Dihydroberberine exhibits synergistic effects with sunitinib on NSCLC NCI‐H460 cells by repressing MAP kinase pathways and inflammatory mediators
por: Dai, Bingling, et al.
Publicado: (2017)

HMQ‐T‐F2 exert antitumour effects by upregulation of Axin in human cervical HeLa cells
por: Dai, Bingling, et al.
Publicado: (2018)

Sanguinarine inhibits epithelial–mesenchymal transition via targeting HIF-1α/TGF-β feed-forward loop in hepatocellular carcinoma
por: Su, Qi, et al.
Publicado: (2019)

TPD7 inhibits the growth of cutaneous T cell lymphoma H9 cell through regulating IL‐2R signalling pathway
por: Zhu, Man, et al.
Publicado: (2019)

Sanguinarine disrupts the colocalization and interaction of HIF‐1α with tyrosine and serine phosphorylated‐STAT3 in breast cancer
por: Su, Qi, et al.
Publicado: (2020)

Vandetanib
por: Vozniak, J. Michael, et al.
Publicado: (2012)

EphB4/ephrinB2 Contributes to Imatinib Resistance in Chronic Myeloid Leukemia Involved in Cytoskeletal Proteins
por: Li, Lin, et al.
Publicado: (2016)

Cantharidin induces apoptosis of human triple negative breast cancer cells through mir-607-mediated downregulation of EGFR
por: Yang, Tianfeng, et al.
Publicado: (2023)

Brucine suppresses colon cancer cells growth via mediating KDR signalling pathway
por: Luo, Wenjuan, et al.
Publicado: (2013)

Apoferritin/Vandetanib Association Is Long-Term Stable But Does Not Improve Pharmacological Properties of Vandetanib
por: Jáklová, Kateřina, et al.
Publicado: (2021)

A novel taspine derivative suppresses human liver tumor growth and invasion in vitro and in vivo
por: WANG, NAN, et al.
Publicado: (2013)

Stevens-Johnson Syndrome Induced by Vandetanib
por: Yoon, Jimi, et al.
Publicado: (2011)

Radiosensitisation of Hepatocellular Carcinoma Cells by Vandetanib
por: Znati, Sami, et al.
Publicado: (2020)

Vandetanib for the Treatment of Metastatic Medullary Thyroid Cancer
por: Degrauwe, Nils, et al.
Publicado: (2012)

Role of vandetanib in the management of medullary thyroid cancer
por: Brassard, Maryse, et al.
Publicado: (2012)

Selective use of vandetanib in the treatment of thyroid cancer
por: Fallahi, Poupak, et al.
Publicado: (2015)

Dermoscopic findings of perifollicular pigmentation associated with vandetanib
por: Cury-Martins, Jade, et al.
Publicado: (2018)

Investigating the effect of vandetanib and celecoxib combination on angiogenesis
por: Qadir, Abdul, et al.
Publicado: (2023)

A novel biphenyl urea derivate inhibits the invasion of breast cancer through the modulation of CXCR4
por: Zhan, Yingzhuan, et al.
Publicado: (2015)

Sanguinarine suppresses migration and metastasis in colorectal carcinoma associated with the inversion of EMT through the Wnt/β‐catenin signaling
por: Zhu, Man, et al.
Publicado: (2020)

Vandetanib (ZD6474) in the Treatment of Medullary Thyroid Cancer
por: Deshpande, Hari, et al.
Publicado: (2011)

Imatinib in Chronic Myeloid Leukemia: an Overview
por: Sacha, Tomasz
Publicado: (2014)

CAY10683 and imatinib have synergistic effects in overcoming imatinib resistance via HDAC2 inhibition in chronic myeloid leukemia
por: Zhang, Tianzhuo, et al.
Publicado: (2020)

Photosensitivity Reactions to Vandetanib: Redevelopment after Sequential Treatment with Docetaxel
por: Son, Young-Min, et al.
Publicado: (2011)

Pharmacokinetic Drug Interactions with Vandetanib during Coadministration with Rifampicin or Itraconazole
por: Martin, Paul, et al.
Publicado: (2012)

Long‐term cardiovascular effects of vandetanib and pazopanib in normotensive rats
por: Cooper, Samantha L., et al.
Publicado: (2019)

Vandetanib induced phototoxic reaction progressed to toxic epidermal necrolysis()
por: Gul, Busra Demirbag, et al.
Publicado: (2022)

Spred2 Modulates the Erythroid Differentiation Induced by Imatinib in Chronic Myeloid Leukemia Cells
por: Yang, Yuefeng, et al.
Publicado: (2015)

Imatinib in chronic myeloid leukemia elderly patients
por: Gugliotta, Gabriele, et al.
Publicado: (2011)

Homoharringtonine suppresses tumor proliferation and migration by regulating EphB4-mediated β-catenin loss in hepatocellular carcinoma
por: Zhu, Man, et al.
Publicado: (2020)

The transcription factor STAT5 drives mutation and imatinib resistance in chronic myeloid leukemia via ROS production
por: Grundschober, Eva, et al.
Publicado: (2011)

Celecoxib suppresses autophagy and enhances cytotoxicity of imatinib in imatinib-resistant chronic myeloid leukemia cells
por: Lu, Ying, et al.
Publicado: (2016)

Clinical utility of vandetanib in the treatment of patients with advanced medullary thyroid cancer
por: Deshpande, Hari, et al.
Publicado: (2011)

A secondary RET mutation in the activation loop conferring resistance to vandetanib
por: Nakaoku, Takashi, et al.
Publicado: (2018)

Evaluating vandetanib in the treatment of medullary thyroid cancer: patient-reported outcomes
por: Fallahi, Poupak, et al.
Publicado: (2019)

Vandetanib Reduces Inflammatory Cytokines and Ameliorates COVID-19 in Infected Mice
por: Puhl, Ana C., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_u2iimna16u31ooj16iur1hvkbt